Figure 2.
Clinical endpoints across study duration. Mean 6MWT distance without imputation (A), mean NT-proBNP concentration (B), and median KCCQ-12 OS and CS scores (C) with ARRY-371797 (PF-07265803) treatment. *P of increases in absolute 6MWT distance vs baseline ≤0.05. 6MWT indicates 6-minute walk test; CS, clinical summary; KCCQ-12, Kansas City Cardiomyopathy Questionnaire short form; NT-proBNP, N-terminal pro-B-type natriuretic peptide; and OS, overall summary.